InDex Pharmaceuticals (publ) today announced that the company will present a poster at the United European Gastroenterology Week (UEGW). UEGW is the largest scientific meeting for gastroenterologists in Europe.
October 26, 2017 - InDex Pharmaceuticals (publ) today announced that the company will present a poster at the United European Gastroenterology Week (UEGW). UEGW is the largest scientific meeting for gastroenterologists in Europe. The congress is held in Barcelona, Spain on October 28 - November 1, 2017.
The poster summarizes the results from a market research study of 148 ulcerative colitis patients in Europe and the US regarding their familiarity with and perceptions of rectally administered medications. Almost all the patients stated that they have used rectally administered products at some point during their disease journey, and the majority of the patients were not concerned about rectal mode of administration. The poster has the title Treatment experience with topical products for Ulcerative Colitis - the patient’s perspective in Europe and the USA, and will be presented during the poster session on Tuesday October 31.
“This study illustrates that the use of topical therapy is acceptable by the majority of ulcerative colitis patients and we are looking forward to share the results with the medical expertise attending the UEGW”, says Peter Zerhouni, CEO of InDex Pharmaceuticals. “Participating in the congress also provides an opportunity for InDex to meet with many of the investigators in our ongoing clinical study CONDUCT - a phase IIb dose optimisation study with the drug candidate cobitolimod for the treatment of ulcerative colitis.”
For more information:
Peter Zerhouni, CEO
Phone: +46 8 508 847 35
E-mail: peter.zerhouni@indexpharma.com
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company’s foremost asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe active ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company’s shares are traded on Nasdaq First North Stockholm. Redeye AB is the company’s Certified Adviser. For more information, please visit www.indexpharma.com
